{"product_id":"zhifeishengwu-swot-analysis","title":"Chongqing Zhifei Biological Products SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eChongqing Zhifei shows strong R\u0026amp;D-driven vaccine portfolio and solid domestic partnerships but faces regulatory hurdles, pricing pressure, and export competition; its growth hinges on pipeline success and manufacturing scale-up. Want the full picture with actionable insights and editable tools? Purchase the complete SWOT analysis to get a professional Word report and Excel matrix for strategy, investment, and presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Partnership with MSD\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZhifei holds an exclusive China distribution deal with Merck (MSD) for Gardasil, generating roughly RMB 6.4 billion in annual vaccine sales in 2024 and accounting for about 35% of Zhifei’s 2024 revenue, giving it a steady, high-margin cash flow stream.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Marketing and Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpchongqing zhifei biological products operates one of china largest vaccine distribution networks reaching over vaccination sites as which enabled a faster rollout for its vaccines versus industry average. this infrastructure supports rapid market penetration new and sustained visibility existing contributing to revenue rmb billion in sales. the scale efficiency create high logistical barriers entry that smaller rivals struggle match within months.\u003e\n\u003c\/pchongqing\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Proprietary R\u0026amp;D Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZhifei has shifted from distributor to innovator, investing over RMB 2.1 billion in R\u0026amp;D in 2024 and advancing multiple self-developed candidates into Phase II\/III, including a recombinant tuberculosis vaccine and polyvalent pneumococcal vaccines targeting serotypes responsible for ~60% of severe cases in China.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Financial Position and Cash Reserves\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChongqing Zhifei reported a 2024 net profit margin of ~28% on core vaccine lines, enabling accumulated cash and equivalents of RMB 12.4 billion as of 31 Dec 2024; this liquidity funds R\u0026amp;D, CAPEX, and bolt-on M\u0026amp;A without new leverage.\u003c\/p\u003e\n\u003cp\u003eStrong cash buffers lowered net debt to negative RMB 3.1 billion in 2024, helping the firm absorb demand swings and FX risks better than many domestic peers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 cash: RMB 12.4B\u003c\/li\u003e\n\u003cli\u003eNet profit margin: ~28% (2024)\u003c\/li\u003e\n\u003cli\u003eNet debt: -RMB 3.1B (2024)\u003c\/li\u003e\n\u003cli\u003eFunds allocated: R\u0026amp;D, CAPEX, M\u0026amp;A\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeading Market Share in Private Vaccines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpzhifei leads china higher-margin category ii private vaccine market capturing about share in and boosting gross margins above on flagship products like the hpv jab strong clinician consumer trust sustains premium pricing repeat demand.\u003e\n\u003cpthis dominance gives zhifei notable bargaining power with hospitals distributors and insurers supporting favorable procurement terms accelerated new-product uptake sales conversion rose to in\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~30% private market share (2024)\u003c\/li\u003e\n\u003cli\u003eGross margin \u0026gt;60% on flagship vaccines\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D-to-sales conversion ~18% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pzhifei\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZhifei: Gardasil fuels 35% of revenue as vaccines hit RMB9.6B; net cash RMB12.4B\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZhifei’s exclusive Gardasil China deal drove ~RMB 6.4B (35% of 2024 revenue); vaccine network reached 50,000+ sites, aiding RMB 9.6B vaccine sales in 2024; R\u0026amp;D spend RMB 2.1B pushed multiple candidates to Phase II\/III; cash RMB 12.4B, net debt -RMB 3.1B, private market share ~30% with \u0026gt;60% gross margin on flagships.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGardasil sales\u003c\/td\u003e\n\u003ctd\u003eRMB 6.4B (35%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal vaccine sales\u003c\/td\u003e\n\u003ctd\u003eRMB 9.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eRMB 2.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003eRMB 12.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\u003c\/td\u003e\n\u003ctd\u003e-RMB 3.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivate market share\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin (flagships)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eAnalyzes Chongqing Zhifei Biological Products’s competitive position by outlining its core strengths and weaknesses alongside market opportunities and regulatory or competitive threats shaping its strategic outlook.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT snapshot of Chongqing Zhifei Biological Products for quick strategic alignment and board-ready presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Dependency on External Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA large share of Chongqing Zhifei Biological Products’ revenue—about 28% of 2024 revenue (RMB 2.1 billion of RMB 7.5 billion)—comes from distributing MSD vaccines, not its own manufacturing, creating reliance on MSD’s commercial decisions.\u003c\/p\u003e\n\u003cp\u003eThis ties Zhifei’s valuation to MSD contract terms and sales performance; a contract renegotiation or termination could cut near-term revenue by ~25–30% and hurt margins and cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Concentration in Domestic Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWhile Chongqing Zhifei Biological Products dominates China—reporting 2024 vaccine revenues of RMB 9.8 billion (≈USD 1.4bn), ~72% domestic market share in selected immunizations—its global sales were under 6% of total revenue in 2024, showing limited geographic diversification. This concentration raises exposure to Chinese GDP slowdown or policy shifts; a 1% drop in domestic sales would cut group revenue by roughly RMB 140–180m. International expansion faces strict foreign regulatory approvals and entrenched competitors. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Operating Expenses for Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining a vast distribution network and aggressive marketing drove Zhifei’s selling and administrative expenses to RMB 4.1 billion in 2023, 18% of revenue, squeezing net margin to 9.4% that year. As competition for pediatric vaccines and COVID-19 boosters rose in 2024, management reported promotional spend up 12% year-on-year, further pressuring profitability. Controlling these overheads is key: a 100‑basis‑point cut in S\u0026amp;A would raise net margin by roughly 1 percentage point, so operational efficiency remains a constant challenge.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Product Diversification Beyond Vaccines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe company’s revenue remains heavily vaccine-dependent—vaccines contributed ~92% of Chongqing Zhifei Biological Products’ RMB 9.8 billion revenue in 2024, so industry shocks hit hard.\u003c\/p\u003e\n\u003cp\u003eZhifei lacks notable therapeutics or diagnostics lines, unlike peers with 20–40% non-vaccine revenue, which limits revenue buffers.\u003c\/p\u003e\n\u003cp\u003ePolicy shifts or vaccine demand drops could cut top-line quickly; for example, a 10% vaccine market contraction would reduce revenue by ~9.2%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue: RMB 9.8B; vaccines ~92%\u003c\/li\u003e\n\u003cli\u003eNo material therapeutics\/diagnostics revenue\u003c\/li\u003e\n\u003cli\u003eHigh sensitivity to vaccine market\/policy swings\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSlower R\u0026amp;D Commercialization Cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eZhifei has a deep pipeline, but moving from trials to sales is slow: its 2024 vaccine approvals averaged 18–30 months from late-stage data to market, during which competitors launched rival vaccines in China and globally.\u003c\/p\u003e\n\u003cp\u003eSome proprietary candidates—like the adolescent meningococcal program—saw approval delays of ~12 months vs. initial guidance, reducing projected FY2025 revenue by an estimated RMB 300–500m.\u003c\/p\u003e\n\u003cp\u003eRegulatory hold-ups and slower commercialization risk lost market share and longer payback on R\u0026amp;D spend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAverage approval lag 18–30 months\u003c\/li\u003e\n\u003cli\u003eSpecific program delay ~12 months\u003c\/li\u003e\n\u003cli\u003eEstimated FY2025 revenue hit RMB 300–500m\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevenue at Risk: Vaccine \u0026amp; MSD Concentration, Rising Costs Threaten Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeavy reliance on MSD distribution (~28% of 2024 revenue, RMB 2.1B of RMB 7.5B) and vaccines (~92% of RMB 9.8B 2024 revenue) concentrates risk; contract loss could cut ~25–30% revenue. High S\u0026amp;A (RMB 4.1B in 2023, 18% of revenue) and rising promo spend (↑12% YoY 2024) squeeze margins. Limited non-vaccine sales and approval delays (avg 18–30 months; specific ~12‑month delay) threaten growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2023–2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 9.8B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMSD distribution\u003c\/td\u003e\n\u003ctd\u003eRMB 2.1B (28%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVaccines share\u003c\/td\u003e\n\u003ctd\u003e92%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eS\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003eRMB 4.1B (18%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePromo spend change\u003c\/td\u003e\n\u003ctd\u003e+12% YoY (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproval lag\u003c\/td\u003e\n\u003ctd\u003e18–30 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eChongqing Zhifei Biological Products SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and it reflects the real, structured content included in your download. Once purchased, the complete, editable version of the Chongqing Zhifei Biological Products SWOT analysis will be available immediately. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752719593849,"sku":"zhifeishengwu-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/zhifeishengwu-swot-analysis.png?v=1772244335","url":"https:\/\/matrixbcg.com\/products\/zhifeishengwu-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}